Antibody specifically binding to CD40 and use thereof

A novel anti-CD40 antibody with specific CDR sequences blocks CD40-CD40L signaling, addressing the limitations of current immunosuppressants by effectively treating autoimmune diseases and chronic inflammatory diseases and suppressing transplant rejection without adverse effects.

WO2025159610A1 Publication Date: 2025-07-31SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
7 Cites 1 Cited by

Patent Information

Application Number
PCT/KR2025/099085
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-24
Filing Date
2025-01-17
Publication Date
2025-07-31

AI Technical Summary

Technical Problem

Current immunosuppressants used for autoimmune diseases and allogeneic islet transplantation have adverse effects, necessitating the development of therapeutically effective anti-CD40 antibodies that can inhibit the CD40/CD40L interaction without causing side effects.

Method used

Development of a novel anti-CD40 antibody with specific complementarity determining regions (CDRs) that block CD40-CD40L signaling, comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences with at least 80% identity to SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively, and its use in pharmaceutical compositions for treating autoimmune diseases, chronic inflammatory diseases, and suppressing immune rejection during transplantation.

Benefits of technology

The anti-CD40 antibody effectively blocks CD40-CD40L signaling, reducing autoantibody production, suppressing T-cell activation, and preventing transplant rejection, thereby treating autoimmune diseases and chronic inflammatory diseases while minimizing adverse effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.
Need to check novelty before this filing date? Find Prior Art